Nucleophilic substitution and ring transformation reactions with 4-chloro-6-ethyl-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione

Hany M. Hassanin

Department of Chemistry, Faculty of Education, Ain Shams University, Roxy 11757, Cairo, Egypt

E-mail: <u>hanyhassnin@yahoo.com</u>

DOI: http://dx.doi.org/10.3998/ark.5550190.0013.634

Abstract

4-Chloro-6-ethyl-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione (3) was obtained by nitration followed by chlorination of 4-hydroxypyranoquinoline-2,5-dione 1. Substitution reactions of compound 3 with various nucleophiles, namely: sodium azide, amines, thiophenol and malononitrile, led to a series of novel 4-sustituted-3-nitropyranoquinolinones. Also, nucleophilic reactions of compound 3 with hydrazine, cyanoguanidine and S-methylisothiourea, involving ring opening-ring closure of the pyranoquinolinedione nucleus, are described.

Keywords: Pyrano[3,2-c]quinolines, nucleophilic substitution, pyrazolinone, furoxan, pyrimidine, ring opening-ring closure

Introduction

Pyrano[3,2-c]quinolinones are known as good synthons for many biologically important substituted quinolinones. Quinolin-2(1H)-one derivatives are of increasing interest since many of these compounds show useful applications as chemotherapeutic agents. For example, some quinolinones are recently reported to have potential as inhibitors for hepatitis C polymerase, ^{1,2} microsomal prostaglandin E_2 synthase-1³ and selective iNOS⁴. Many quinolinone derivatives have been found active as antimalarial parasite agents, ⁵ antiamebics, and antischistosomal agents, ⁶⁻⁸ and to have antibacterial, ^{9,10} antiproliferative and antitubulin, ¹¹ anti-hepatitis B virus (HBV)^{12,13} anti-HIV-1¹⁴ activities.

Pyrano[3,2-c]quinolinones are able to undergo ring opening at C-2 and ring reclosure at C-4 when reacted with binucleophiles. ^{15,16} The chemistry of nucleophilic reactions involving ring opening–ring closure (RORC) of 4-chloro-3-nitropyrano[3,2-c]quinolinone **3** attracted our attention due to the expected higher reactivity of the o-chloronitro heterocycles and to the paucity of their literature reports. ¹⁷⁻¹⁹ On the other hand, the combination of a pyrazole and/or

pyrimidine nucleus with the quinoline moiety in one molecular framework is reported to confer biological activity. Herein we report the synthesis of the novel 4-chloro-6-ethyl-3-nitro-pyrano[3,2-c]quinoline-2,5-dione (3) and a study of its chemical behavior towards some nitrogen, sulfur and carbon nucleophiles to obtain a new series of 4-substituted-3-nitropyranoquinolinediones. Also, we use compound 3 to prepare 4-hydroxyquinolinones incorporating a pyrazolone or pyrimidine and/or triazolopyrimidine ring at position 3, with the possibility to show biological activity.

Results and Discussion

Heating *N*-ethylaniline with two equivalents of diethyl malonate gave 4-hydroxypyrano[3,2-c]-quinoline-2,5(6H)-dione (1).^{23,24} Nitration of compound 1 has been reported with a mixture of conc. nitric acid and conc. sulfuric acid in boiling acetic acid.²⁵ We herein report for application of a known modification under substantial milder conditions, at room temperature using sodium nitrite as catalyst.¹⁷ *Roschger et al.*¹⁷ had applied this methodology in similar case of 4-hydroxyquinolin-2-ones, and according to this modification, catalytic effect of the nitrite was attributed to an initial nitrosation at position 3 and subsequent *in situ* oxidation of the nitroso intermediate to the desired nitro product 2 (Scheme 1). Chlorination of compound 2 with phosphoryl chloride in the presence of triethylamine afforded 4-chloro-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione 3 (Scheme 1). The IR and 1H NMR spectra of compound 3 confirmed the absence of the hydroxy group. The mass spectrum of compound 3 showed two molecular ion peaks at m/z 320 [M⁺] and m/z 322 [M⁺+2], these data support the identity of the structure and confirm the presence of the chlorine atom.

Scheme 1

The substitution of the chlorine by an azide group was achieved by the reaction of compound 3 with sodium azide, in *N*-methylpyrrolidone, at room temperature (Scheme 2). The IR spectrum of the product 4 showed characteristic absorption band at 2150 cm⁻¹ attributed to the azido group. Organic azides with suitable *ortho* substituents are known to undergo thermal cyclization with loss of N₂ gas. Ring closure to the fused furoxan 5 was achieved by thermolysis of the azide 4 in refluxing nitrobenzene (Scheme 2). The IR spectrum of furoxan 5 showed characteristic absorption bands at 1448 cm⁻¹ assigned to the C=N–O, while the stretching vibration of the fragment O—N→O was seen at 1301 cm⁻¹ (as the recently reported for furoxan ring²⁸). The mass spectrum of compound 5 showed the molecular ion peak at m/z 299.

Nucleophilic substitution of the chlorine atom at position 4 of compound 3 by various nucleophiles such as amines, thiophenol, and malononitrile could be carried out under mild conditions. Thus, reaction of compound 3 with benzylamine led to the 4-benzylamino derivative 6a (Scheme 2). The ¹H NMR spectrum of compound 6a showed a new characteristic singlet signal at δ 4.26 assigned to the methylene protons of benzyl group, in addition to one exchangeable signal at δ 10.00 ppm due to NH proton. The reaction of compound 3 with aniline, in the presence of triethylamine, yielded the 4-phenylamino derivative 6b (Scheme 2). Notable in the ¹H NMR spectrum of compound **6b** are the integral count of protons in the aromatic region revealing the presence of nine protons due to the aromatic protons of the quinoline and phenyl groups. In addition, the presence of a deuterium-exchangeable singlet appeared as a broad signal at δ 9.56 due to N-H. Similarly, condensation of compound 3 with piperidine gave the 4-piperidinyl derivative 7 (Scheme 2). The ¹H NMR spectrum of compound 7 showed the signals due to the piperidinyl group as three characteristic multiplets at δ 1.33, 1.62 and 2.98. The mass spectrum showed the molecular ion at m/z 369, in agreement with the formula weight (369.38). Treatment of compound 3 with thiophenol, in the presence of triethylamine, afforded the thioether 8. In the ¹³C NMR spectrum of 8 sixteen separate signals were observed at 95.8-160.9 ppm belonging to the aromatic carbon atoms, while the two carbonyls were seen at 170.6 and 170.9 ppm.

The introduction of a cyano group into compound **3** by Rosenmund-Braun aromatic cyanodechlorination with copper(I) cyanide in high-boiling solvents gave a mixture of compounds,²⁹ in which separation attempts failed. However, another recently described method³⁰ allowed us to introduce the carbonitrile function at the 4-position of compound **3** under relatively mild conditions. That is by a two-step reaction, the first step is converting Cl group to the reactive tosyloxy leaving group, at the 4-position, via the reaction of compound **3** with sodium *p*-toluenesulfonate to give 4-tosylate **9** (Scheme 3), which was then treated with potassium cyanide to afford the 4-cyanopyranoquinolinedione **10**.

The IR spectrum of compound **10** showed characteristic absorption bands at 2213, 1733, 1629 cm⁻¹, attributed to C \equiv N, C \equiv O_{pyrone} and C \equiv O_{quinolinone}, respectively. Also, the mass spectrum showed the molecular ion peak at m/z 311 which is in good agreement with the formula weight (311.26). Reaction of compound **3** with malononitrile in ethanol containing few drops of triethylamine afforded 2-(pyranoquinolin-4-yl)malononitrile **11** (Scheme 3). The IR spectrum of

compound **11** showed characteristic absorption bands at 2207, 2159 (2 C \equiv N), 1737 (C=O_{pyrone}) and 1623 cm⁻¹ (C=O_{quinolone}). The malononitrile proton was observed at δ 5.57 ppm in the 1 H NMR spectrum, while the sp^{3} hybridized carbon atom of the malononitrile group appeared at δ 85.6 ppm in the 13 C NMR spectrum.

Scheme 2

Scheme 3

The compound **3** was allowed to react with some binucleophilic reagents to prepare 4-hydroxyquinolinones bearing a pyrazole or pyrimidine moiety in one molecular framework. Treatment of compound **3** with hydrazine hydrate in boiling DMF effected α -pyrone ring opening followed by ring closure (RORC) with loss of HCl, leading to the pyrazolone **12** (Scheme 4). The ¹H NMR spectrum of compound **12** showed signals due to three exchangeable protons characteristic for 2 NH_{pyrazole} and OH_{quinolinone} at δ 11.30, 13.41 and 13.93 ppm. Also, the structure of compound **12** was supported by its mass spectrum which exhibited a molecular ion peak at m/z 316. Reaction of compound **3** with cyanoguanidine as 1,3-binucleophile, afforded the pyrimidine derivative **13** (Scheme 4). The IR spectrum of pyrimidine **13** showed the presence of absorption bands at 3190 and 2199 cm⁻¹, due to the NH and C \equiv N groups, respectively. Furthermore, the ¹H NMR spectrum of compound **13** showed three deuterium-exchangeable singlet signals assignable to the two NH and the OH protons at δ 12.62, 13.40 and 13.95.

Scheme 4

The reaction of chloropyranoquinolinedione **3** with *S*-methylisothiourea in DMF afforded the methylsulfanylpyrimidine derivative **14** (Scheme 5). A methyl signal was observed at δ 2.83 ppm in the 1 H NMR spectrum of **14**, and at δ 22.1 ppm in the 13 C NMR spectrum. The reaction of methylsulfanyl-pyrimidine derivative **14** with hydrazine hydrate in DMF produced the hydrazinopyrimidine **15** (Scheme 5). The elemental analysis showed absence of sulfur in the product revealing the replacement of the methylsulfanyl group. IR spectrum exhibited stretching vibrational bands at 3335, 3191 and 3100 cm⁻¹ due to NH₂ and NH groups. 1 H NMR spectrum displayed two signals due to deuterium exchangeable protons at δ : 7.16 and 8.25 (–NH-NH₂). Moreover, the mass spectrum revealed a molecular ion peak at m/z 358 [M⁺] as the base peak, in agreement with the calculated molecular weight of the product **15**. Thermal cyclocondensation of the hydrazinopyrimidine **15** with triethyl orthoformate, in DMF, was carried out to get the triazolopyrimidine derivatives **16**. The 1 H NMR spectrum of the cyclized product **16** revealed the

disappearance of the NH₂ signal which was appeared in the 1 H NMR spectrum of compound **15** at δ 7.16 ppm, in addition to the appearance of characteristic singlet signal at δ 8.22 ppm assigned to the CH_{triazolopyrimidin}. Mass spectrum of **16** recorded the molecular ion peak at m/z 368 which agree well with the molecular formula and supports the identity of the structure.

Scheme 5

Conclusions

4-Chloro-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione **3** was conveniently obtained *via* simple successful reactions. Many nucleophilic substitution reactions of the activated chloro leaving group in the compound **3** were carried out using facile and mild conditions. Combination of pyrazole and/or pyrimidine nuclei with quinolinone moiety in one molecular-frame was achieved *via* RORC heterocyclization reaction of compound **3** with some binucleophiles.

Experimental Section

General. Melting points were determined on a digital Stuart SMP3 apparatus. Infrared spectra were measured on Perkin-Elmer 293 spectrophotometer (cm⁻¹), using KBr disks. ¹H NMR spectra were measured on Gemini-300BB spectrometer 300 MHz (at 75MHz for ¹³C), or Jeol Eca-500 MHz (at 125 MHz for ¹³C) using DMSO- d_6 or CDCl₃ as a solvent and TMS (δ) as the internal standard. Mass spectra were obtained using GC-2010 Shimadzu GC- Mass spectrometer (70 eV). Elemental microanalyses were performed on a Perkin–Elmer CHN-2400 analyzer.

6-Ethyl-4-hydroxy-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione (2). A suspension of compound 1 (2.57 g, 10 mmol) in glacial acetic acid (20 mL) was treated with concentrated nitric acid (2 mL, 30 mmol) and sodium nitrite (0.03 g, 0.5 mmol) to start slightly exothermic reaction. The starting material dissolved, followed immediately by precipitating the product. After stirring for 15 minutes the product was filtered, washed with water and crystallized from DMF/MeOH to give compound 2 as yellow crystals, yield (2.85 g, 94%), m.p. 242–243 °C (the previously reported ²⁵ 90%, 240-242).

4-Chloro-6-ethyl-3-nitropyrano[3,2-*c*]**quinoline-2,5**(6*H*)-**dione** (3). Dry triethylamine (1 mL) was added to a solution of compound **2** (3.02 g, 10 mmol) in phosphoryl chloride (15.2 mL, 100 mmol). The mixture was refluxed for 1 h. The excess solvent was removed by distillation and the residue poured on ice water (100 mL). The precipitate so formed was filtered, washed with water, dried and crystallized from EtOH to give compound **3** as yellow crystals, yield (2.75 g, 85%), m.p. 206–208 °C. IR (KBr, cm⁻¹): 3081 (CH_{arom}), 2975, 2930 (CH_{aliphatic}), 1732 (C=O_{pyranone}), 1636 (C=O_{quinolinone}), 1616 (C=C), 1567, 1371 (NO₂), 756 (C-Cl). ¹H NMR (500 MHz, DMSO-*d*₆, δ): 1.19 (t, 3H, J = 6.9 Hz, CH₂CH₃), 4.34 (q, 2H, J = 6.9 Hz, CH₂CH₃), 7.38 (t, 1H, J = 7.2 Hz, H-9), 7.67 (d, 1H, J = 8.0 Hz, H-7), 7.82 (t, 1H, J = 7.2 Hz, H-8), 8.11 (d, 1H, J = 8.0 Hz, H-10). ¹³C NMR (125 MHz, DMSO-*d*₆, δ): 13.1 (CH₃), 38.2 (CH₂), 99.3 (C_{4a}), 113.3 (C₇), 117.0 (C_{10a}), 118.9 (C₉), 124.8 (C₁₀), 125.5 (C₈), 138.8 (C_{6a}), 153.3 (C₄), 159.4 (C_{10b} as C-O), 163.1 (C₃), 164.0 (C₅ as C=O), 166.4 (C₂ as C=O). M/z (relative intensity): 322 [M⁺ +2, 13], 321 [M⁺ +1, 23], 320 [M⁺, 48], 319 (41), 308 (13), 292 (12), 248 (16), 218 (21), 190 (33), 162 (16), 146 (100), 132 (47), 77 (61). Anal. Calcd for C₁₄H₉N₂O₅Cl (320.69): C, 52.44; H, 2.83; N, 8.74; Cl, 11.06%. Found: C, 52.20; H, 2.79; N, 8.23; Cl, 10.98%.

4-Azido-6-ethyl-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione (4). A solution of compound **3** (3.20 g, 10 mmol) and sodium azide (0.98 g, 15 mmol) in *N*-methylpyrrolidone (30 mL) was stirred at room temperature for 3 h. then the reaction mixture was poured into 500 mL of ice water, the precipitate so formed was filtered, washed with water and dried and crystallized from methanol to give compound **4** as yellow crystals, yield (2.94 g, 90%), m.p. 128 °C, partial decomposition, resolidifies and melts again at 171-173°C. IR (KBr, cm⁻¹): 3081 (CH_{arom.}), 2978, 2874 (CH_{aliphatic}), 2150 (N₃), 1719 (C=O_{pyranone}), 1632 (C=O_{quinolinone}), 1610 (C=C), 1565, 1366 (NO₂). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.22 (t, 3H, J = 6.9 Hz, CH₂CH₃), 4.28 (q, 2H, J = 6.9 Hz, CH_2 CH₃), 7.23 (t, 1H, J = 7.6 Hz, H-9), 7.63 (d, 1H, J = 8.0 Hz, H-7), 7.89 (t, 1H, J = 7.6 Hz, H-8), 8.17 (d, 1H, J = 8.0 Hz, H-10). M/z (relative intensity): 328 [M⁺ +1, 5], 327 [M⁺, 8], 308 (5), 306 (5), 297 (5), 256 (7), 213 (15), 191 (7), 169 (8), 149 (32), 133 (10), 129 (19), 69 (100). Anal. Calcd for C₁₄H₉N₅O₅ (327.26): C, 51.38; H, 2.77; N, 21.40%. Found: C, 51.14; H, 2.53; N, 21.12%.

5-Ethyl-[1,2,5]oxadiazolo[3',4':4,5]pyrano[3,2-c]quinoline-4,11(5*H***)-dione 1-oxide (5). A solution of compound 4** (3.27 g, 10 mmol) in nitrobenzene (50 mL) was refluxed until evolution of nitrogen gas had stopped (about 15 minutes). Then the solvent was removed by distillation and the residue poured on diethyl ether (30 mL). The product was filtered, washed with diethyl ether and crystallized from toluene to give compound **5** as colorless crystals, yield (2.65g, 88%), m.p. 179-181°C. IR (KBr, cm⁻¹): 3088 (CH_{arom.}), 2979, 2933 (CH_{aliphatic}), 1735 (C=O_{pyranone}), 1668 (C=O_{quinolinone}), 1625 (C=N), 1615 (C=C), 1561, 1448, 1301, 1002, 820, 731 (assigned to furoxane ring). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.27 (t, 3H, J = 6.4 Hz, CH₂CH₃), 4.39 (q, 2H, J = 6.4 Hz, CH_2 CH₃), 7.58 (t, 1H, J = 7.2 Hz, H-9), 7.91 (d, 1H, J = 8.4 Hz, H-7), 7.92 (t, 1H, J = 7.2 Hz, H-8), 8.18 (d, 1H, J = 8.4 Hz, H-10). ¹³C NMR (125 MHz, DMSO- d_6 , δ): 12.1 (CH₃), 38.2 (CH₂), 99.2, 113.6, 118.6, 121.2, 124.5, 128.5, 129.5, 136.1, 157.4, 158.2, 163.2, 164.4. M/z (relative intensity): 300 [M⁺ +1, 15], 299 [M⁺, 77], 298 (20), 270 (11), 258 (19), 257 (100), 256 (12), 229 (35), 215 (19), 185 (22), 146 (22), 132 (47), 100 (33), 77 (48). Anal. Calcd for C₁₄H₉N₃O₅ (299.24): C, 56.19; H, 3.03; N, 14.04%. Found: C, 56.04; H, 2.93; N, 13.74%.

4-Benzylamino-6-ethyl-3-nitropyrano[3,2-c]quinoline-2,5(6H)-dione (6a). A mixture of compound 3 (3.20 g, 10 mmol) and benzylamine (1.09 mL, 10 mmol) in N-methylpyrrolidone (30 mL) was stirred at room temperature for 4 h. The product was precipitated with 100 mL of ice water, filtered, washed with water and crystallized from AcOH to give compound **6** as pale brown crystals, yield (3.55 g, 90%), m.p. 191-193°C. IR (KBr, cm⁻¹): 3081 (CH_{arom.}), 2975, 2930 (CH_{aliphatic}), 1732 (C=O_{pyranone}), 1636 (C=O_{quinolinone}), 1616 (C=N), 1559 (C=C), 1567, 1371 (NO₂). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.19 (t, 3H, J = 7.2 Hz, CH₂CH₃), 4.26 (s, 2H), 4.47 (q, 2H, J = 7.2 Hz, CH_2 CH₃), 6.90 – 8.06 (m, 9H, Ar-H), 10.00 (s, 1H, NH exchangeable with D₂O). M/z (relative intensity): 391 [M⁺, 40], 254 (91), 240 (75), 229 (15), 201 (13), 161 (68), 146 (43), 144 (25), 120 (63), 117 (35), 104 (25), 92 (10), 78 (100). Anal. Calcd for C₂₁H₁₇N₃O₅ (391.39): C, 64.45; H, 4.38; N, 10.74%. Found: C, 64.44; H, 3.93; N, 10.58%.

6-Ethyl-3-nitro-4-phenylaminopyrano[3,2-c]quinoline-2,5(6H)-dione (6b). A mixture of compound **3** (3.20 g, 10 mmol) and aniline (0.91 mL, 10 mmol), in *N*-methylpyrrolidone (50 mL) containing few drops of triethylamine, was stirred at room temperature for 4 h. The product was precipitated with ice water (100 mL), filtered, washed with water and crystallized from toluene to give compound **6b** as pale yellow crystals, yield (3.10 g, 82%), m.p. 202-204°C. IR (KBr, cm⁻¹): 3195 (NH), 3060 (CH_{arom.}), 2963, 2868 (CH_{aliphatic}), 1725 (C=O_{pyranone}), 1632 (C=O_{quinolinone}), 1592 (C=C). M/z (relative intensity): 377 [M⁺, 57], 367 [M⁺ -1, 44], 348 (41), 333 (55), 295 (55), 269 (89), 217 (47), 190 (55), 189 (100), 146 (52), 132 (94), 77 (66). ¹H NMR (500 MHz, DMSO-*d*₆, δ): 1.20 (t, 3H, J = 6.8 Hz, CH₂CH₃), 4.33 (q, 2H, J = 7.0 Hz, CH₂CH₃), 7.26 – 7.42 (m, 6H, J = 7.2 Hz, H-9 and Ar-H), 7.56 (d, 1H, J = 8.0 Hz, H-7), 7.82 (t, 1H, J = 7.2 Hz, H-8), 8.11 (d, 1H, J = 8.0 Hz, H-10), 9.56 (s, 1H, NH exchangeable with D₂O). M/z (relative intensity): 377 [M⁺, 57], 376 [M⁺ -1, 45], 350 (55), 333 (55), 332 (42), 310 (59), 295 (55), 288 (57), 269 (90), 255 (42), 241 (74), 217 (47), 189 (100), 174 (87), 161 (75), 146 (52),

132 (94), 77 (67). Anal. Calcd for $C_{20}H_{15}N_3O_5$ (377.36): C, 63.66; H, 4.01; N, 11.14%. Found: C, 63.45; H, 3.83; N, 11.07%.

6-Ethyl-3-nitro-4-piperidin-1-yl-pyrano[3,2-*c*]**quinoline-2,5**(*6H*)-**dione** (7). A mixture of compound **3** (3.20 g, 10 mmol) and piperidine (0.99 mL, 10 mmol), in *N*-methylpyrrolidone (30 mL) was stirred at room temperature for 4 h. The product was precipitated with ice water (100 mL) and after standing 24 h, filtered, washed with water and crystallized from toluene to give compound **7** as pale yellow crystals, yield (2.51 g, 68%), m.p. 180-182°C. IR (KBr, cm⁻¹): 3092 (CH_{arom.}), 2985, 2930 (CH_{aliphatic.}), 1733 (C=O_{pyranone.}), 1633 (C=O_{quinolinone.}), 1610 (C=N), 1566 (C=C), 1565, 1367 (NO₂). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.19 (t, 3H, J = 6.8 Hz, CH₂CH₃), 1.33 (m, 2H), 1.62 (m, 4H), 2.98 (m, 4H), 4.24 (q, 2H, J = 6.8 Hz, CH₂CH₃), 7.36 (t, 1H, J = 7.4 Hz, H-9), 7.71 (d, 1H, J = 8.0 Hz, H-7), 7.98 (t, 1H, J = 7.4 Hz, H-8), 8.16 (d, 1H, J = 8.0 Hz, H-10). M/z (relative intensity): 369 [M⁺, 13], 368 (4), 350 (12), 351 (11), 342 (13), 304 (11), 300 (11), 263 (10), 257 (4), 185 (12), 149 (22), 141 (49), 139 (100), 111 (60), 98 (22), 85 (10), 75 (23). Anal. Calcd for C₁₉H₁₉N₃O₅ (369.38): C, 61.78; H, 5.18; N, 11.38%. Found: C, 61.64; H, 5.03; N, 11.09%.

6-Ethyl-3-nitro-4-phenylsulfanylpyrano[3,2-*c*]quinoline-2,5(6*H*)-dione (8). A mixture of compound **3** (3.20 g, 10 mmol), thiophenol (1.05 mL, 10 mmol) and few drops of triethylamine in *N*-methylpyrrolidone (30 mL) was stirred at room temperature for 1 h. The product was precipitated with ice water (100 mL), filtered, washed with water and crystallized from toluene to give compound **8** as pale brown crystals, yield (2.95 g, 75%), m.p. 222-224°C. IR (KBr, cm⁻¹): 3084 (CH_{arom.}), 2974, 2937 (CH_{aliphatic}), 1731 (C=O_{pyranone}), 1670 (C=O_{quinolinone}), 1613 (C=C), 1569, 1376 (NO₂). ¹H NMR (500 MHz, CDCl₃, δ): 1.24 (t, 3H, *J* = 6.0 Hz, CH₂CH₃), 4.41 (q, 2H, *J* = 7.2 Hz, *CH*₂CH₃), 7.25 – 8.23 (m, 9H, Ar-H). ¹³C NMR (125 MHz, DMSO-*d*₆, δ): 12.7 (CH₃), 36.8 (CH₂), 95.8 (C_{4a}), 112.2, 112.4, 114.9, 115.1, 119.1, 122.2, 122.4, 124.6, 128.6, 128.8, 134.5, 138.6, 148.0 (C₄), 154.1 (C_{10b} as C-O), 160.9 (C₃), 170.6 (C₅ as C=O), 170.9 (C₂ as C=O). M/z (relative intensity): 394 [M⁺, 12], 393 (10), 323 (23), 322 (100), 321 (60), 294 (65), 286 (38), 268 (46), 237 (20), 221 (19), 169 (13), 161 (16), 146 (23), 132 (34), 130 (20), 120 (32), 119 (27), 108 (25), 77(42). Anal. Calcd for C₂₀H₁₄N₂O₅S (394.41): C, 60.91; H, 3.58; N, 7.10; S, 8.13%. Found: C, 60.70; H, 3.51; N, 7.04%.

4-Methyl(6-ethyl-3-nitro-2,5-dioxo-5,6-dihydro-2H-pyrano[**3,2-***c*]**quinolin-4-yl) benzene-sulfonate** (**9**). A mixture of compound **3** (3.20 g, 10 mmol) and sodium *p*-toluenesulfonate (1.94 g, 10 mmol) in DMF (50 mL) was heated at 120 °C for 20 h. The product was precipitated with ice water (100 mL), filtered, washed with water and crystallized from ethanol to give **9** as pale yellow crystals, yield (3.14, 69%), m.p. 292-294°C. IR (KBr, cm⁻¹): 3084 (CH_{arom.}), 2973, 2872 (CH_{aliphatic}), 1723 (C=O_{pyranone}), 1632 (C=O_{quinolinone}), 1613 (C=C), 1566, 1372 (NO₂). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.20 (t, 3H, J = 6.9 Hz, CH₂CH₃), 2.43 (s, 3H, CH₃), 4.33 (q, 2H, J = 6.9 Hz, CH₂CH₃), 7.34 – 7.47 (m, 3H, H-9 and Ar-H), 7.56 -7.67 (m, 3H, H-7 and Ar-H), 7.83 (t, 1H, J = 7.2 Hz, H-8), 8.09 (d, 1H, J = 8.0 Hz, H-10). ¹³C NMR (125 MHz, DMSO- d_6 , δ): 16.1 (CH₃), 20.3 (PhCH₃), 38.2 (CH₂), 92.3, 112.2, 113.6, 114.4, 115.7, 117.1, 119.7, 127.3, 128.2, 129.2, 130.5, 134.6, 138.5, 146.2, 146.4, 152.3, 152.5, 157.3. M/z (relative intensity): 457 [M⁺

+1, 13], 456 [M⁺, 44], 441 (11), 428 (14), 310 (37), 281 (41), 258 (11), 257 (51), 229 (100), 228 (53), 201 (43), 173 (26), 145 (46), 120 (22), 104 (26), 77 (48). Anal. Calcd for $C_{21}H_{16}N_2O_8S$ (456.43): C, 55.26; H, 3.53; N, 6.14; S, 7.02%. Found: C, 55.94; H, 3.54; N, 6.16; S, 7.05%.

6-Ethyl-3-nitro-2,5-dioxo-5,6-dihydro-2H-pyrano[**3,2-***c*]**quinoline-4-carbonitrile** (**10**). A mixture of compound **9** (4.56 g, 10 mmol) and potassium cyanide (0.79 g, 12 mmol) in dry DMF (60 mL) was stirred at 70 °C vigorously for 4 h. Then, the mixture was poured into ice/water (200 mL) and . The obtained solid was filtered by suction, washed with water, dried and crystallized from dioxane to give compound **10** as yellow crystals, yield (2.4 g, 77%), m.p. 286-288 °C. IR (KBr, cm⁻¹): 3080 (CH_{arom.}), 2924, 2855 (CH_{aliphatic}), 2213 (CN), 1733 (C=O_{pyrane}), 1629 (C=O_{quinolinone}), 1611 (C=C). ¹H NMR (300 MHz, DMSO-*d*₆, δ): 1.20 (t, 3H, *J* = 6.8 Hz, CH₂CH₃), 4.35 (q, 2H, *J* = 6.8 Hz, *CH*₂CH₃), 7.55 (t, 1H, *J* = 7.2 Hz, H-9), 7.91 (d, 1H, *J* = 8.0 Hz, H-7), 7.95 (t, 1H, *J* = 7.2 Hz, H-8), 8.14 (d, 1H, *J* = 8.0 Hz, H-10). M/z (relative intensity): 312 [M⁺ +1, 7], 311 [M⁺, 26], 298 (22), 297 (88), 285 (29), 268 (35), 239 (13), 191 (21), 190 (22), 161 (24), 146 (40), 133 (66), 130 (28), 119 (44), 104 (30), 77(100), 63(75). Anal. Calcd for C₁₅H₉N₃O₅ (311.26): C, 57.88; H, 2.91; N, 13.50%. Found: C, 57.64; H, 2.80; N, 12.74%.

2-(6-Ethyl-3-nitro-2,5-dioxo-5,6-dihydro-2H-pyrano[3,2-c]quinolin-4-yl)-malononitrile (11). A mixture of compound **3** (3.20 g, 10 mmol) and malononitrile (0.70 g, 10 mmol), in absolute ethanol (50 mL) containing few drops of triethylamine, was stirred for 2 h. The solid deposited after cooling was filtered and crystallized from methanol to give compound **11** as yellow crystals, yield (2.27 g, 65%), m.p. 216-218 °C. IR (KBr, cm⁻¹): 3048 (CH_{arom}), 2974, 2935, 2852 (CH_{aliphatic}), 2207, 2159 (2CN), 1737 (C=O_{pyranone}), 1623 (C=O), 1570 (C=C). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.26 (t, 3H, J = 7.8 Hz, CH₂CH₃), 4.38 (q, 2H, J = 7.8 Hz, CH₂CH₃), 5.57 (s, 1H, CH(CN)₂), 7.52 (t, 1H, J = 7.2 Hz, H-9), 7.84-7.89 (m, 2H, H-7 and H-8), 8.12 (d, 1H, J = 8.0 Hz, H-10). ¹³C NMR (75 MHz, DMSO- d_6 , δ): 12.7 (CH₃), 37.8 (CH₂), 85.6 (CH(CN)₂), 99.5 (C_{4a}), 113.0, 116.1, 116.3, 123.9, 124.3, 124.6, 134.6, 134.8, 137.5, 157.1, 157.5, 162.0, 165.5. M/z (relative intensity): 350 [M⁺, 3], 349 (2), 330 (4), 326 (4), 301 (27), 300 (79), 286 (6), 285 (16), 284 (20), 271 (27), 257 (57), 265 (45), 243 (39), 230 (40), 229 (100), 228 (48), 200 (44), 187 (35), 173(40), 144 (33), 116 (40), 77(48), 64 (58). Anal. Calcd for C₁₇H₁₀N₄O₅ (350.29): C, 58.29; H, 2.88; N, 15.99%. Found: C, 58.14; H, 2.83; N, 15.74%.

1-Ethyl-4-hydroxy-3-(4-nitro-5-oxo-2,5-dihydro-1H-pyrazol-3-yl)-quinolin-2(1*H***)-one (12).** A mixture of compound **3** (3.20 g, 10 mmol) and hydrazine hydrate (0.58 mL, 12 mmol), in DMF (30 mL), was heated under reflux for 4h. The solid deposited after cooling was filtered and crystallized from acetic acid to give compound **12** as colorless crystals, yield (2.49 g, 79%), m.p. 290-292°C. IR (KBr, cm⁻¹): 3366 (OH), 3206 (NH), 3030 (CH_{arom.}), 2917 (CH_{aliphatic}), 1668 (C=O_{pyrazol}), 1632 (C=O_{quinolinone}), 1586 (C=C). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.23 (t, 3H, J = 7.4 Hz, CH₂CH₃), 4.32 (q, 2H, J = 7.4 Hz, CH₂CH₃), 7.33 (t, 1H, J = 7.2 Hz, H-6), 7.59 (d, 1H, J = 8.0 Hz, H-8), 7.93 (t, 1H, J = 7.2 Hz, H-7), 8.07 (d, 1H, J = 8.0 Hz, H-5), 11.30, 13.41 (2s, 2H, 2NH exchangeable with D₂O), 13.93 (s, 1H, OH exchangeable with D₂O). ¹³C NMR (75

MHz, DMSO- d_6 , δ): 22.0 (CH₃), 47.2 (CH₂), 98.5 (C₃), 119.3, 122.1, 125.3, 125.7, 133.8, 134.1, 145.1, 147.6, 152.3, 168.1, 175.4. M/z (relative intensity): 316 [M⁺, 35], 308 (34), 249 (34), 224 (40), 199 (35), 192 (40), 186 (40), 177 (42), 153 (40), 149 (44), 135 (37), 128 (46), 118 (40), 116 (38), 111 (46), 101 (48), 85 (27) 67(37), 59(100). Anal. Calcd for C₁₄H₁₂N₄O₅ (316.28): C, 53.17; H, 3.82; N, 17.71%. Found: C, 53.04; H, 3.83; N, 17.54%.

6-(1-Ethyl-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl)-5-nitro-4-oxo-3,4-dihydro-1H-

pyrimidin-2-ylidene-cyanamide (**13**). A mixture of compound **3** (3.02 g, 10 mmol) and cyanoguanide (0.85 g, 10 mmol), in DMF (50 mL), was heated under reflux for 4h. The solid deposited after cooling was filtered and crystallized from dioxane to give compound **13** as yellow crystals, yield (2.61 g, 71%), m.p. 268-270 °C. IR (KBr, cm⁻¹): 3435 (OH), 3190 (NH), 3030 (CH_{arom.}), 2978, 2928 (CH_{aliphatic}), 2199 (CN), 1646 (C=O_{quinolinone}), 1616 (C=N), 1586 (C=C). 1 H NMR (300 MHz, DMSO- d_6 , δ): 1.23 (t, 3H, J = 7.0 Hz, CH₂CH₃), 4.33 (q, 2H, J = 7.0 Hz, CH_2 CH₃), 7.33 (t, 1H, J = 7.2 Hz, H-6), 7.59 (d, 1H, J = 8.0 Hz, H-8), 7.94 (t, 1H, J = 7.2 Hz, H-7), 8.07 (d, 1H, J = 8.0 Hz, H-5), 12.62, 13.40 (2s, 2H, 2NH exchangeable with D₂O), 13.95 (s, 1H, OH exchangeable with D₂O). M/z (relative intensity): 368 [M⁺, 90], 367 [11], 355(37), 337 (38), 322 (43), 298 (45), 297 (53), 293 (48), 273 (46), 232 (40), 213 (29), 205 (31), 147 (49), 131 (61), 118 (40),103 (49), 77(43), 69(100). 13 C NMR (75 MHz, DMSO- d_6 , δ): 12.8 (CH₃), 37.4 (CH₂), 103.8 (C₃), 116.0, 118.7, 122.5, 123.4, 128.1, 131.6, 136.5, 138.5, 140.4, 156.7, 157.4, 166.6, 184.6. Anal. Calcd for C₁₆H₁₂N₆O₅ (368.31): C, 52.18; H, 3.28; N, 22.82%. Found: C, 52.06; H, 3.18; N, 22.27%.

1-Ethyl-4-hydroxy-3-(2-methylsulfanyl-5-nitro-6-oxo-3,6-dihydro-pyrimidin-4-yl)-quinolin-2(1*H***)-one (14). A mixture of compound 3** (3.20 g, 10 mmol) and S-methylisothiourea (0.09 g, 10 mmol), in DMF (30 mL), was heated under reflux for 4h. The yellow crystals obtained after cooling was filtered and recrystallized from DMF/EtOH to give compound **14** as yellow crystals, yield (2.46 g, 66%), m.p. 244–246 °C. IR (KBr, cm⁻¹): 3366, 3285, 3100 (OH, NH), 2971 (CH_{aliphatic}), 1655 (C=O_{quinolinone} and C=O_{pyrimidine}), 1605, 1588, 1570 (C=N and C=C). ¹H NMR (500 MHz, CDCl₃, δ): 1.34 (t, 3H, J = 6.6 Hz, CH₂CH₃), 2.83 (t, 3H, SCH₃), 4.36 (q, 2H, J = 6.6 Hz, CH₂CH₃), 7.32 (t, 1H, J = 7.2 Hz, H-6), 7.55-7.82 (m, 2H, H-8 and H-7), 8.19 (d, 1H, J = 8.0 Hz, H-5), 13.14 (s, 1H, NH exchangeable with D₂O), 13.39 (s, H, OH exchangeable with D₂O). ¹³C NMR (125 MHz, DMSO-d₆, δ): 12.6 (CH₃), 22.1 (SCH₃), 43.7 (CH₂), 101.2, 111.8, 114.7, 116.0, 122.2, 123.5, 124.2, 133.9, 137.3, 138.7, 154.7, 157.3, 158.3. M/z (relative intensity): 375 [M⁺ +1, 37], 374 [M⁺, 100], 326 (20), 311 (61), 297 (17), 195 (35), 280 (16), 252 (13), 237 (4), 194 (12), 150 (24), 136 (25), 111 (35), 94 (23), 59 (14). Anal. Calcd for C₁₆H₁₄N₄O₅S (374.38): C, 51.33; H, 3.77; N, 14.97; S, 8.56%. Found: C, 51.12; H, 3.63; N, 14.74, S, 8.36%.

1-Ethyl-4-hydroxy-3-(2-hydrazino-5-nitro-6-oxo-3,6-dihydro-pyrimidin-4-yl)-quinolin-

2(1*H***)-one (15).** A mixture of compound **14** (3.74 g, 10 mmol), and hydrazine hydrate (0.58 mL, 12 mmol), in DMF (30 mL), was refluxed for 2h. The precipitate so formed on hot was filtered and crystallized from acetic acid, to give compound **15** as coulorless crystals, yield (2.68 g, 75%), m.p. 322–324 °C. IR (KBr, cm⁻¹): 3411, 3335, 3191, 3100 (OH, NH₂, NH), 3070 (CH_{arom.}), 2979, 2937 (CH_{aliphatic}), 1654 (C=O_{quinoline} and C=O_{pyrimidine}), 1600, 1567 (C=N and

C=C). 1 H NMR (500 MHz,DMSO- d_{6} , δ): 1.25 (t, 3H, J = 6.4 Hz, CH₂CH₃), 4.37 (q, 2H, J = 6.6 Hz, CH₂CH₃), 7.16 (br, 2H, NH₂ exchangeable with D₂O), 7.50 (t, 1H, J = 7.2 Hz, H-6), 7.85-7.90 (m, 2H, H-8 and H-7), 8.13 (d, 1H, J = 8.0 Hz, H-5), 8.25, 11.48 (2s, 2H, 2NH exchangeable with D₂O), 14.56 (s, 1H, OH exchangeable with D₂O). M/z (relative intensity): 359 [M⁺+1, 25], 358 [M⁺, 100], 357 (9), 342 (8), 341 (30), 315 (6), 266 (9), 253 (5), 146 (2), 132 (7), 128 (10), 118 (15), 92 (8), 91 (39), 78 (10), 77 (86), 65 (14). Anal. Calcd for C₁₅H₁₄N₆O₅ (358.32): C, 50.28; H, 3.94; N, 23.45%. Found: C, 50.24; H, 3.83; N, 23.34%.

1-Ethyl-4-hydroxy-3-(1,5-dihydro-6-nitro-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidin-7-yl)-quinolin-2(1*H***)-one** (**16**). To a solution of compound **15** (3.58 g, 10 mmol) in DMF (30 mL), triethyl orthoformate (2.04 mL, 12 mmol) was added and heated under reflux for 2h. The precipitate so formed on hot was filtered and crystallized from acetic acid, to give compound **16** as coulorless crystals, yield (2.55 g, 69%), m.p. above 325 °C. IR (KBr, cm⁻¹): 3400 (OH), 3292, 3190 (NH), 3078 (CH_{arom.}), 2970, 2938 (CH_{aliphatic}), 1668 (C=O_{pyrimidine}), 1632 (C=O_{quinoline}) 1610, 1577 (C=N and C=C). ¹H NMR (300 MHz, DMSO- d_6 , δ): 1.24 (t, 3H, J = 6.6 Hz, CH₂CH₃), 4.38 (q, 2H, J = 6.6 Hz, CH₂CH₃), 7.55 (t, 1H, J = 7.2 Hz, H-6), 7.79-7.98 (m, 2H, H-8 and H-7), 8.13 (d, 1H, J = 8.0 Hz, H-5), 8.22 (s, 1H, CH_{triazolopyrimidin}), 11.33(s, 1H, NH exchangeable with D₂O), 14.50 (s, 1H, OH exchangeable with D₂O). M/z (relative intensity): 369 [M⁺ +1, 26], 368 [M⁺, 100], 367 (57), 340 (50), 324 (24), 313 (80), 296 (21), 285 (15), 258 (6), 257 (12), 220 (10), 171 (11), 163 (10), 146 (40), 133 (66), 130 (28), 119 (44), 104 (30), 77(75), 63(75). Anal. Calcd for C₁₆H₁₂N₆O₅ (368.31): C, 52.18; H, 3.28; N, 22.82%. Found: C, 52.15; H, 3.58; N, 23.54%.

References

- 1. Tedesco, R.; Chai, D.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; Johnston, V. K.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Shaw, A. N.; Valko, K. L.; Wiggall, K. J.; Zimmerman M. N.; Duffy, K. J. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4354.
- 2. Hutchinson, D. K.; Flentge, C. A.; Donner, P. L.; Wagner, R.; Maring, C. J.; Kati, W. M.; Liu, Y.; Masse, S. V.; Middleton, T.; Mo, H.; Montgomery, D.; Jiang, W. W.; Koev, G.; Beno, D. W. A.; Stewart, K. D.; Stoll, V. S.; Molla, A.; Kempf, D. J. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1876.
- 3. Shiro, T.; Takahashi, H.; Kakiguchi, K.; Inoue, Y.; Masuda, K.; Nagata, H.; Tobe, M. *Bioorg. Med. Chem. Lett.* **2012**, 22, 285.
- 4. Durón, S. G.; Lindstrom, A.; Bonnefous, C.; Zhang, Hui.; Chen, Xiaohong.; Symons, K. T.; Sablad, M.; Rozenkrants N.; Zhang Y.; Wang, Li.; Yazdani, Nahid.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. *Bioorg. Med. Chem. Lett.* **2012**, 22, 1237.
- 5. Ghorab, M. M.; Heiba, H. I.; Amin, N. E. *Pharmazie* **1999**, *54*, 226.

- 6. Mariah, F. E. L. J. Chem. Res. **2009**, *9*, 588.
- 7. Duraipandiyan, V.; Ignacimuthu, S. J. Ethnopharm. 2009, 123, 494.
- 8. El-Taweel, F. M. A.; Sofan, M. A.; Mashaly, M. A.; Hanna, M. A.; Elagamey, A. A. *Pharmazie* **1990**, *45*, 671.
- 9. Tavares, L. C.; Johann, S.; Alves, T. M. A.; Guerra, J. C.; de Souza-Fagundes, E. M.; Cisalpino, P. Silva.; Bortoluzzi, A. J.; Caramori, G. F.; Piccoli. R. M.; Braibante, H. T. S.; Braibante, M. E. F.; Pizzolatti, M. G. *Eur. J. Med. Chem.* **2011**, *46*, 4448.
- 10. Kalkhambkar, R. G.; Aridoss, G.; Kulkarni, G. M.; Bapset, R. M.; Mudaraddi, T. Y.; Premkumar, N.; Jeong, Y. T. *Monatsh Chem.* **2011**, *142*, 305.
- 11. Magedov, I. V.; Manpadi, M.; Ogasawara, M. A.; Dhawan, A. S.; Rogelj, S.; Van Slambrouck, S.; Steelant, W. F. A.; Evdokimov, N. M.; Uglinskii, P. Y.; Elias, E. M.; Knee, E. J.; Tongwa, P.; Antipin, Y. M.; Kornienko, A. *J. Med. Chem.* **2008**, *51*, 2561.
- 12. Guo, R.-H; Zhang, Q.; Ma, Y.-B.; Huang, X.-Y; Luo, J.; Wang, L.-J; Geng, C.-A; Zhang, X.-M; Zhou, J.; Jiang, Z.-Y; Chen, J.-J. *Bioorg. Med. Chem.* **2011**, *19*, 1400.
- 13. Guo, R.-H.; Zhang, Q.; Ma,Y.-B.; Luo, J. Geng, C.-A.; Wang, L.-J.; Zhang, X.-M.; Zhou, J.; Jiang, Z.-Y.; Chen. J.-J. *Eur. J. Med. Chem.* **2011**, *46*, 307.
- 14. Curreli, F.; Zhang, H.; Zhang, X.; Pyatkin, I.; Victor, Z.; Altieri, A.; Debnath, A. K. *Bioorg. Med. Chem.* **2011**, *19*, 77.
- 15. Abass, M.; Othman, E. S.; Hassan, A. Synth. Commun. 2007, 37, 607.
- 16. Abass, M; Mostata, B. B. Bioorg. Med. Chem. 2005, 13, 6133.
- 17. Roschger, P.; Fiala, W.; Stadlbauer, W. J. Heterocyclic Chem. 1992, 29, 225.
- 18. Tabacović, K.; Tabacović, I.; Trkovnik, M.; Trinajstić, N. Liebigs Ann. Chem. 1983, 1901.
- 19. Jung, J-C.; Oh, S.; Kim, W-K.; Park, W-K.; Kong, J. Y.; Park, O-S. *J. Heterocyclic Chem.*, **2003**, *40*, 617.
- 20. López Rivilli, M. J.; Moyano, E. L.; Yranzo, G. I. Tetrahedron Lett. 2010, 51, 478.
- 21. Christodoulou, M. S.; Liekens, S.; Kasiotis, K. M.; Haroutounian, S. A. *Bioorg. Med. Chem.* **2010**, *18*, 4338.
- 22. Pawlas, J.; Vedso, P.; Jakobsen, P.; Huusfeldt, P. O.; Begtrup, M. J. Org. Chem. 2000, 65, 9001.
- 23. Abonía, R.; Cuervo, P.; Hursthouse, M. B.; Cobo, J.; Glidewell, C. Acta Cryst. Sect. C: Crystal Str. Commun. 2010, 66, 44.
- 24. Gao, W.-T.; Hou, W.-D.; Zheng, M.-R.; Tang, L.-J. Synth. Commun. 2010, 40, 732.
- 25. El-Taweel, F. M. A.; Sowellim, S. Z. A.; Elagamey, A. G. *Boll. Chim. Farmac.* **1998**, *137*, 325.
- 26. Stadlbauer, W.; Prattes, S.; Fiala, W. J. Heterocyclic Chem. 1998, 35, 627.
- 27. Hojas, G.; Fiala, W.; Stadlbauer, W. J. Heterocyclic Chem. 2000, 37, 1559.
- 28. Ovchinnikov, I. V.; Strelenko, Yu. A.; Popov, N. A.; Finogenov, A. O.; Makhova, N. N.; *Russ. Chem. Bull.*, *Int. Ed.*, **2011**, *60* (5), 855.
- 29. (a) Hassner, A.; Stumer, C. Tetrahedron Organic Chemistry Series Vol. 11: Organic Syntheses Based on Name Reactions and Unnamed Reactions (Baldwin, J. E.; Magnus, P.

- D., Eds.), Pergamon, Oxford, 1994. (b) Krauch, H.; Kunz, W.; Nonnenmacher, E.; *Reaktionen der Chemie*, Dr, Verlag, A. H. Heidelberg, **1976**.
- 30. Ahvale, A. B.; Prokopcová, H.; Šefčovičová, J.; Steinschifter, W.; Täubl, A. E.; Uray, G.; Stadlbauer, W. Eur. J. Org. Chem. 2008, 563.